TEALS Study update
Researchers will be recruiting 90 people across NSW, QLD, SA, WA and VIC who meet the criteria for enrolment to participate in the TEALS Study - a multi-centre Phase 2 clinical trial to investigate the safety, tolerability and effectiveness of a drug called Tecfidera in people with MND (The study to Assess the Efficacy and Safety of Tecfidera in Patients with Amyotrophic Lateral Sclerosis - TEALS, Study ID ACTRN12618000534280).